Northwire Canada EditionFriday, October 16, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4188.20 +0.4% SILVER 57.13 −0.0% COPPER 6.57 +0.1% OIL 98.88 +0.9% PALLADIUM 1116.00 −1.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0% BVA 0.780 +2.6% ONAU 0.530 +1.9% FMR 0.225 +0.0% GSVR 0.350 +2.9% PHNM 0.345 +1.5% GOLD 4188.20 +0.4% SILVER 57.13 −0.0% COPPER 6.57 +0.1% OIL 98.88 +0.9% PALLADIUM 1116.00 −1.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0% BVA 0.780 +2.6% ONAU 0.530 +1.9% FMR 0.225 +0.0% GSVR 0.350 +2.9% PHNM 0.345 +1.5%
Other

NurExone Biologic Advances Manufacturing and Regulatory Roadmap with Independent Batch Consistency Results for Exosome Production

By The Northwire Desk — AI Analysis Feb 10, 2026 · 16:04 NRX · 0.64 NurExone Biologic Inc.
NRX · Price

Executive Summary

  • Independent proteomic analysis of four NurExone exosome production batches demonstrated high batch‑to‑batch consistency, supporting CMC readiness for a potential IND filing.
  • The protein fingerprint revealed several therapeutic proteins absent in commercial reference exosomes, indicating a differentiated biological profile for inflammation control and nerve repair.
  • NurExone re‑engaged Russo Partners for an additional 3–6 month PR/IR services term at US$15,000 per month, pending TSXV approval.

Key Details

  • Proteomic Findings: Four independent production batches showed a highly consistent protein “fingerprint” across functional categories (EV identity, ECM/guidance, antioxidant, anti‑inflammatory, trophic signaling).
  • Differentiation: Proteins detected only in NurExone samples included PDGFRB, LAMA4, ARHGEF1, PEX19, TPST1, BDH2, GALK1, CARS1, PACSIN3, CD320, and IL1R1.
  • CMC Implication: Results strengthen evidence of repeatable manufacturing and quality testing, a key milestone toward IND‑enabling activities and clinical‑grade production.
  • Operational Outlook: Company pursuing small‑scale clinical manufacturing capability in Israel and evaluating U.S. scale‑up through Exo‑Top Inc., subject to financing and timing considerations.
  • Russo Partners Engagement: Extension of services for 3–6 months at US$15,000/month; either party may terminate with 30‑day notice; pending TSXV approval.
  • CEO Quote: “Each step towards the clinic is a de‑risking step… This independent assessment provides additional evidence of our manufacturing process control.” – Dr. Lior Shaltiel, CEO.

Notable Quotes

“Consistent exosome production is a core bioengineering milestone that underpins clinical‑grade manufacturing. This independent assessment provides additional evidence of our manufacturing process control.” – Dr. Lior Shaltiel, Chief Executive Officer.

Read the original news release →

More from NurExone Biologic Inc.

Jun 30, 2026 · 08:31

Dilutive financing at a discount underscores cash burn concerns in pre-revenue exosome developer

Financings Jun 24, 2026 · 17:01

Early-stage exosome developer secures Mexican distribution MOU while navigating a tight cash runway and going concern warning.

M&A / Property Jun 01, 2026 · 08:02

NurExone Advances Preclinical Milestones and Secures Minor Capital, But Cash Runway Narrows as Burn Rate Accelerates

Earnings May 19, 2026 · 16:04

NurExone Expands IP Portfolio with South Korea Patent Grant Amidst Manufacturing Push

Other May 14, 2026 · 16:05

NurExone’s EU Program Nod Underscores Exosome Platform’s Promise, But Cash Burn Keeps Investors on Edge

Other Apr 27, 2026 · 16:03

Patent Portfolio Expansion Masks Underlying Liquidity Constraints in Exosome Developer

M&A / Property